Ignite Creation Date:
2025-12-24 @ 10:44 PM
Ignite Modification Date:
2025-12-29 @ 7:52 PM
Study NCT ID:
NCT04512235
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-18
First Post:
2020-08-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Sponsor:
Alexion Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-11-03
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-04-08
Completion Date Type:
ESTIMATED
First Submit Date:
2020-08-10
First Submit QC Date:
None
Study First Post Date:
2020-08-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-17
Last Update Post Date:
2025-12-18
Last Update Post Date Type:
ESTIMATED